AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Sanjeev Kumar Panchal has stepped down as Managing Director of AstraZeneca Group. The company has appointed Praveen Rao ...